Has Gopalan Sridhar received payments from drug or device companies?

Yes. Drug and device makers reported $1,517 in general payments to Gopalan Sridhar across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gopalan Sridhar did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gopalan Sridhar come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gopalan Sridhar

Pediatrics · Reading, PANPI 1063403764

Payments from drug & device makers

$1,517in general payments, 2019–2025

Across 88 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$295
Cranial Technologies, Inc$264
Merck$254
Pfizer$218
Takeda Pharmaceuticals U.S.A., Inc.$72
Kowa Pharmaceuticals America, Inc.$69
plus $346 from 12 others

What the payments were for

Food & beverage$1,48998%
Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	17	$295
Cranial Technologies, Inc	17	$264
Merck	13	$254
Pfizer	15	$218
Takeda Pharmaceuticals U.S.A., Inc.	4	$72
Kowa Pharmaceuticals America, Inc.	4	$69
Tris Pharma Inc	3	$47
Seqirus USA Inc	2	$41
Sobi, Inc	2	$40
Sanofi Pasteur Inc.	2	$37
Neurelis, Inc.	2	$29
Incyte Corporation	1	$27
Biomarin Pharmaceutical Inc.	1	$24
Ironshore Pharmaceuticals Inc.	1	$24
Phadia US Inc.	1	$23
Shire North American Group Inc	1	$22
Biomerieux Inc	1	$20
Aytu Biopharma, Inc.	1	$12

How this compares

$1,517 in reported general payments places this provider in the 90th percentile of 1,849 pediatrics providers in Pennsylvania.

See all pediatrics providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AbrysvoRsv Vacc, Pref A And Pref B/Pf	29	$8,797
ShingrixVaricella-Zoster Ge/As01b/Pf	35	$7,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerAbrysvo	$218	$8,79729 claims
GSKShingrix	$295	$7,29935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,849 pediatrics providers in Pennsylvania.

Payments from drug & device makers

Who reported the general payments

How this compares

Most prescribed under Part D

Companies that both paid and supply prescribed drugs

Other pediatrics in Reading